dc.creatorGarcía González, Paulina
dc.creatorMaggi, Jaxaira
dc.creatorSchinnerling, Katina
dc.creatorSepúlveda Gutiérrez, Alejandro
dc.creatorSoto, Lilian
dc.creatorNeira, Oscar
dc.creatorMehdi, Ahmed M.
dc.creatorNel, Hendrik J.
dc.creatorPesce, Bárbara
dc.creatorAravena, Octavio
dc.creatorMolina, María Carmen
dc.creatorCatalán, Diego
dc.creatorThomas, Ranjeny
dc.creatorVerdugo Salgado, Ricardo
dc.date.accessioned2019-10-30T15:23:54Z
dc.date.available2019-10-30T15:23:54Z
dc.date.created2019-10-30T15:23:54Z
dc.date.issued2019
dc.identifierFrontiers in Immunology, Volumen 10, Issue MAY, 2019,
dc.identifier16643224
dc.identifier10.3389/fimmu.2019.01171
dc.identifierhttps://repositorio.uchile.cl/handle/2250/172347
dc.description.abstractCopyright © 2019 García-González, Maggi, Schinnerling, Sepúlveda-Gutiérrez, Soto, Neira, Mehdi, Nel, Pesce, Aravena, Molina, Catalán, Thomas, Verdugo and Aguillón.The potential of tolerogenic dendritic cells (tolDCs) to shape immune responses and restore tolerance has turn them into a promising therapeutic tool for cellular therapies directed toward immune regulation in autoimmunity. Although the cellular mechanisms by which these cells can exert their regulatory function are well-known, the mechanisms driving their differentiation and function are still poorly known, and the variety of stimuli and protocols applied to differentiate DCs toward a tolerogenic phenotype makes it even more complex to underpin the molecular features involved in their function. Through transcriptional profiling analysis of monocyte-derived tolDCs modulated with dexamethasone (Dex) and activated with monophosphoryl lipid A (MPLA), known as DM-DCs, we were able to identify MYC as one of the transcriptional regulators of several genes differentially expressed on DM-DCs compared to MPLA-matured DCs (M-DCs) and untreated/immature DCs (DCs) as revealed by Ingenuity Pathway Analysis (IPA) upstream regulators evaluation. Additionally, MYC was also amidst the most upregulated genes in DM-DCs, finding that was confirmed at a transcriptional as well as at a protein level. Blockade of transactivation of MYC target genes led to the downregulation of tolerance-related markers IDO1 and JAG1. MYC blockade also led to downregulation of PLZF and STAT3, transcription factors associated with immune regulation and inhibition of DC maturation, further supporting a role of MYC as an upstream regulator contributing to the regulatory phenotype of DM-DCs. On the other hand, we had previously shown that fatty acid oxidation, oxidative metabolism and zinc homeostasis are amongst the main biological functions represented in DM-DCs, and here we show that DM-DCs exhibit higher intracellular expression of ROS and Zinc compared to mature M-DCs and DCs. Taken together, these findings suggest that the regulatory profile of DM-DCs is partly shaped by the effect of the transcriptional regulation of tolerance-inducing genes by MYC and the modulation of oxidative metabolic processes and signaling mediators such as Zinc and ROS.
dc.languageen
dc.publisherFrontiers Media S.A.
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceFrontiers in Immunology
dc.subjectDC transcription factors
dc.subjectDexamethasone-modulated and MPLA-activated DC
dc.subjectROS metabollism in DC
dc.subjectTolerance mechanism
dc.subjectTolerogenic dendritic cells (tDC)
dc.subjectZinc metabollism in DC
dc.titleRegulation of tolerogenic features on dexamethasone-modulated MPLA-activated dendritic cells by Myc
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución